Abraxis actively seeking global partner for Abraxane

By Elaine Rigoli

Tampa, Fla., Sept. 28 - Abraxis BioScience, Inc. said Thursday that it is now seeking a global partner for rights to Abraxane.

The Los Angeles-based biopharmaceutical company said its focus is to have Abraxane be the taxane of choice.

To do this, the company said it wants to establish a comprehensive line that focuses on breast and lung cancer, which represents more than 60% to 70% of the taxane opportunities.

The company's European filing has been approved, said Patrick Soon-Shiong, chairman and chief executive officer, at the UBS Global Life Sciences conference in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.